Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants

Autor: Brian Rice, Ellen White, Ann Sullivan, Sheena McCormack, Monica Desai, Alan McOwan, Mitzy Gafos, David White, Charlotte O’Halloran, David Dunn
Rok vydání: 2019
Předmět:
Adult
Male
Crystal methamphetamine
medicine.medical_specialty
Adolescent
Anti-HIV Agents
Substance-Related Disorders
Sexual Behavior
Human immunodeficiency virus (HIV)
030508 substance abuse
Medicine (miscellaneous)
HIV Infections
medicine.disease_cause
Emtricitabine
Pre-exposure prophylaxis (PrEP)
Article
Gay
bisexual and other men who have sex with men (GBM)
Medication Adherence
law.invention
Men who have sex with men
Sexual and Gender Minorities
Young Adult
03 medical and health sciences
0302 clinical medicine
Mephedrone
Randomized controlled trial
law
Humans
Medicine
030212 general & internal medicine
Hiv acquisition
Reproductive health
business.industry
Prevention
Emtricitabine
Tenofovir Disoproxil Fumarate Drug Combination
Health Policy
HIV
Middle Aged
Adherence
Family medicine
Female
Pre-Exposure Prophylaxis
Self Report
0305 other medical science
business
Chemsex
Follow-Up Studies
medicine.drug
Zdroj: The International Journal on Drug Policy
ISSN: 0955-3959
DOI: 10.1016/j.drugpo.2019.10.007
Popis: BACKGROUND: Pre-exposure prophylaxis (PrEP) is a novel HIV prevention method whereby HIV-negative individuals take the drugs tenofovir and emtricitabine to prevent HIV acquisition. Optimal adherence is critical for PrEP efficacy. Chemsex describes sexual activity under the influence of psychoactive drugs, in the UK typically; crystal methamphetamine, gamma-hydroxybutyrate(GHB) and/or mephedrone. Chemsex drug use has been associated with increased HIV transmission risk among gay, bisexual and other men who have sex with men (GBM) and poor ART adherence among people living with HIV. This study assessed whether self-reported chemsex events affected self-reported daily PrEP adherence among PROUD study participants. METHODS: The PROUD study was an open-label, randomised controlled trial, conducted in thirteen English sexual health clinics, assessing effectiveness of TruvadaⓇ-PrEP among 544 HIV-negative GBM. The study reported an 86% risk-reduction of HIV from daily PrEP. Participants were asked about chemsex engagement at follow-up visits. Monthly self-reports of missed PrEP tablets were aggregated to assess adherence between visits. Univariable and multivariable regression analyses were performed to test for associations between chemsex and reporting less than seven out of seven intended doses(
Databáze: OpenAIRE
Externí odkaz: